Jeffrey Stein, an insider at IDEAYA Biosciences, Inc. (IDYA), has acquired a significant stake in the company. On March 2, 2026, Stein purchased 50,000 shares of IDYA for approximately $1,648,000, at an average price of $32.96 per share.
This substantial acquisition by an insider is often interpreted as a signal of confidence in the company's future performance.
IDEAYA Biosciences, Inc. operates in the biotechnology sector, focusing on developing targeted therapies for cancer. The company's pipeline includes novel compounds aimed at addressing specific genetic mutations driving tumor growth.